Last reviewed · How we verify
Glargine insulin vs regular insulin
Glargine insulin is a long-acting basal insulin that binds to insulin receptors to lower blood glucose, while regular insulin is a short-acting insulin with faster onset and shorter duration.
Glargine insulin is a long-acting basal insulin that binds to insulin receptors to lower blood glucose, while regular insulin is a short-acting insulin with faster onset and shorter duration. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Glargine insulin vs regular insulin |
|---|---|
| Sponsor | University of Pittsburgh |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Both drugs activate insulin receptors on muscle, fat, and liver cells to promote glucose uptake and storage. Glargine insulin has a peakless profile with a duration of ~24 hours, providing steady basal glucose control. Regular insulin has a faster onset (30 minutes to 1 hour) and shorter duration (5-8 hours), making it suitable for mealtime glucose management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) (NA)
- A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) (PHASE3)
- Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management (PHASE4)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) (PHASE4)
- RCT Glargine vs NPH for Treatment of DM in Pregnancy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glargine insulin vs regular insulin CI brief — competitive landscape report
- Glargine insulin vs regular insulin updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI